TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←
▶ 1:40 · $HIMS · $LLY · FINALLY! Hims & Hers + Eli Lilly
episode briefing
Asymmetric Investing

FINALLY! Hims & Hers + Eli Lilly

2026-04-24 · 3 company · 3 thematic
sentiment
1 bull0 bear2 neu
speakers
travis hoium

Travis Hoium hosts the Asymmetric Investing podcast/YouTube channel and manages the Asymmetric portfolio. He conducts fundamental research using Fiscal AI and focuses on platform business models, healthcare technology, and consumer subscription businesses. He discloses holding Hims & Hers as one of his largest positions.

quote
“This is one of the biggest holdings I have in the Asymmetric portfolio, just a little over a $6 billion market cap today. Price-to-earnings multiple looks high at about 55, but the ton of growth in the business. Management is only expectin…”
—travis hoium
now playing · $HIMS · $LLY
$HIMS···bullish· high· postravis hoium
Hims & Hers transitions to platform model with Eli Lilly partnership, membership economics drive bullish thesis
Hims & Hers is shifting from vertical integration to a platform model where low-margin GLP-1 prescriptions attract users to a high-margin $150/month membership, similar to Costco'…
$LLY···neutral· mediumtravis hoium
Eli Lilly partners with Hims & Hers to distribute Zepbound and Found Deo via Lilly Direct
Eli Lilly is leveraging Hims & Hers as a distribution channel for its GLP-1 products (Zepbound vials, QuickPens, and oral Found Deo) through Lilly Direct pharmacy fulfillment, pay…
$NVO···neutral· lowtravis hoium
Novo Nordisk's Ozempic and Wegovy already on Hims & Hers platform as precedent for Lilly deal
Novo Nordisk established the partnership model with Hims & Hers last month for Ozempic and Wegovy, setting the precedent for the new Eli Lilly agreement with similar low-margin pr…